Skip to content
Search for:
The Society
Board of Directors
Scientific Advisory Council
Contact
Events Calendar
Mentorship Program
Rare Disease Task Force
BOD Trainee Representatives
Awards & Grants
Lifetime Achievement Award
Young Investigator Award
Dr. Alan M. Gewirtz Memorial Scholarships
Award for Science Outreach or Patient Advocacy
Paper of the Year Awards
Poster Awards
Local & Regional Delivery Grants
Travel Grants
Science News
Recent Articles
President’s Pick and Perspective
Journal
Archive
Educational Video Library
OSWG Whitepapers
Support for Ukrainian Scientists
Job Board
Employer Profiles
Employer Registration / Login
Events
Annual Meetings
2024 Annual Meeting
2023 Annual Meeting
Past Annual Meetings
2022 Annual Meeting
2022 Annual Meeting
Agenda
Abstracts & Awards
Exhibitors
Sponsors
Venue & Travel
2021 Annual Meeting
2020 Annual Meeting
Webinars
Events Calendar
2024 Event Registration
Membership
Become A Member or Renew Membership
Featured Members
2024 Event Registration
Search for:
Phosphorothioate modified oligonucleotide-protein interactions
OTS
Antisense/RNase H
,
Reviews
July 5, 2020
SHARE
Post Views:
966
Crooke ST, Vickers TA, Liang XH.
Nucleic Acids Res. 2020 Jun 4;48(10):5235-5253.
Pubmed
Previous
Next
Related articles
How to Develop and Prove High-Efficiency Selection of Ligands from Oligonucleotide Libraries: A Universal Framework for Aptamers and DNA-Encoded Small-Molecule Ligands
How to Develop and Prove High-Efficiency Selection of Ligands from Oligonucleotide Libraries: A Universal Framework for Aptamers and DNA-Encoded Small-Molecule Ligands
April 23rd, 2021
Recent progress in non-native nucleic acid modifications
Recent progress in non-native nucleic acid modifications
April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome
April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
April 23rd, 2021
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome
April 23rd, 2021
Antisense Technology: A Review.
Antisense Technology: A Review.
March 15th, 2021
Page load link
Go to Top